QUESTIONS OVER UDG’S DISASTROUS SELL-OFF

Brendan McAtamney

LAST YEAR it was almost impossible to decipher the results for UDG Healthcare (previously United Drug) and, this year, the damage done to the group by a disastrous sell-off has again been well disguised. There are serious questions to be asked about the sale of UDG’s Aquilant subsidiary, which resulted in a loss of $100m…. Read more »

I'm a Subscriber